Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
14. November 2023 16:05 ET
|
Onconova Therapeutics, Inc.
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
07. November 2023 16:05 ET
|
Onconova Therapeutics, Inc.
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
Onconova Therapeutics to Provide Corporate Update and Announce Second Quarter 2023 Financial Results on August 10, 2023
03. August 2023 16:05 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and...
Onconova Therapeutics Presents Preclinical Data on Narazaciclib at the 17th International Conference on Malignant Lymphoma
14. Juni 2023 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., June 14, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and...
Onconova Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
15. Mai 2023 16:18 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer
11. Mai 2023 08:00 ET
|
Onconova Therapeutics, Inc.
Prior data provide clinical proof-of-concept for narazaciclib’s mechanism of action in endometrial cancer Preliminary data from trial’s Phase 1 portion expected in 4Q 2023 NEWTOWN, Pa., May 11,...